ArticleJAMA oncology2016
Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation: The Breast Cancer Quality of Care (BQUAL) Study.
Article in JAMA oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- CAMONCO 2: Results From a Randomized Controlled Trial Comparing Open Dialogue About Complementary Alternative Medicine and Standard Care on Patients' Quality of Life.JCO oncology practice · 2025Trial
- Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial.European journal of cancer (Oxford, England : 1990) · 2024Trial
- Polypharmacy, over-the-counter medications, and aromatase inhibitor adherence in early-stage breast cancer.Breast cancer research and treatment · 2024Trial
- Effects of a patient-tailored integrative oncology intervention in the relief of pain in palliative and supportive cancer care.Journal of cancer research and clinical oncology · 2021Trial
- Implementation of a Mindful Walking Intervention in Breast Cancer Patients After Their Primary Oncologic Treatment: Results of a Qualitative Study Within a Randomized Controlled Trial.Integrative cancer therapiesTrial
- Microbial production of eumelanin from a desert-derived Aspergillus terreus: statistical optimization, comprehensive characterization, and in silico insights into breast cancer-associated targets.Microbial cell factories · 2026Article
- Self-reported racial and ethnic discrimination in patient-provider interactions and the initiation of adjuvant therapies for breast cancer in the pathways study.Breast cancer research and treatment · 2026Article
- Response rates, survival status and adverse events of placebo in randomized control trials for hepatocellular carcinoma: A meta-analysis.World journal of hepatology · 2025Article
- Article
- Racial disparities in initiation of chemotherapy among breast cancer patients with discretionary treatment indication in the state of Georgia.Breast cancer research and treatment · 2024Article
- Impact assessment of integrated-pathy on cancer-related fatigue in cancer patients: an observational study.Journal of health, population, and nutrition · 2024Observational
- The Incidence and Management of Cancer-Related Anorexia During Treatment with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors.Cancer management and research · 2023Review
- Exploring neurotransmitters and their receptors for breast cancer prevention and treatment.Theranostics · 2023Review
- The Self-Administered Use of Complementary and Alternative Medicine (CAM) Supplements and Antioxidants in Cancer Therapy and the Critical Role of Nrf-2-A Systematic Review.Antioxidants (Basel, Switzerland) · 2022Review
- Article
- Protective and Therapeutic Efficacy of Hesperidin versus Cisplatin against Ehrlich Ascites Carcinoma-Induced Renal Damage in Mice.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Impact of Open Dialogue about Complementary Alternative Medicine-A Phase II Randomized Controlled Trial.Cancers · 2022Article
- Patient Perspectives on the Development of a Novel Mobile Health (mHealth) Application for Dietary Supplement Tracking and Reconciliation-A Qualitative Focus Group Study.Global advances in health and medicine · 2022Article
- Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue.Breast cancer research and treatment · 2021Article
- Using the Google™ Search Engine for Health Information: Is There a Problem? Case Study: Supplements for Cancer.Current developments in nutrition · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
importanceNot all women initiate clinically indicated breast cancer adjuvant treatment. It is important for clinicians to identify women at risk for noninitiation.
objectiveTo determine whether complementary and alternative medicine (CAM) use is associated with decreased breast cancer chemotherapy initiation. DESIGN, SETTING, AND
participantsIn this multisite prospective cohort study (the Breast Cancer Quality of Care [BQUAL] study) designed to examine predictors of breast cancer treatment initiation and adherence, 685 women younger than 70 years with nonmetastatic invasive breast cancer were recruited from Columbia University Medical Center, Kaiser Permanente Northern California, and Henry Ford Health System and enrolled between May 2006 and July 31, 2010. Overall, 306 patients (45%) were clinically indicated to receive chemotherapy per National Comprehensive Cancer Network guidelines. Participants were followed for up to 12 months. EXPOSURES: Baseline interviews assessed current use of 5 CAM modalities (vitamins and/or minerals, herbs and/or botanicals, other natural products, mind-body self-practice, mind-body practitioner-based practice). CAM use definitions included any use, dietary supplement use, mind-body use, and a CAM index summing the 5 modalities. MAIN OUTCOMES AND MEASURES: Chemotherapy initiation was assessed via self-report up to 12 months after baseline. Multivariable logistic regression models examined a priori hypotheses testing whether CAM use was associated with chemotherapy initiation, adjusting for demographic and clinical covariates, and delineating groups by age and chemotherapy indication.
resultsA cohort of 685 women younger than 70 years (mean age, 59 years; median age, 59 years) with nonmetastatic invasive breast cancer were recruited and followed for up to 12 months to examine predictors of breast cancer treatment initiation. Baseline CAM use was reported by 598 women (87%). Chemotherapy was initiated by 272 women (89%) for whom chemotherapy was indicated, compared with 135 women (36%) for whom chemotherapy was discretionary. Among women for whom chemotherapy was indicated, dietary supplement users and women with high CAM index scores were less likely than nonusers to initiate chemotherapy (odds ratio [OR], 0.16; 95% CI, 0.03-0.51; and OR per unit, 0.64; 95% CI, 0.46-0.87, respectively). Use of mind-body practices was not related to chemotherapy initiation (OR, 1.45; 95% CI, 0.57-3.59). There was no association between CAM use and chemotherapy initiation among women for whom chemotherapy was discretionary. CONCLUSIONS AND RELEVANCE: CAM use was high among patients with early-stage breast cancer enrolled in a multisite prospective cohort study. Current dietary supplement use and higher number of CAM modalities used but not mind-body practices were associated with decreased initiation of clinically indicated chemotherapy. Oncologists should consider discussing CAM with their patients during the chemotherapy decision-making process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.